Pharmavite Amends CholestOff Claims After FTC Joins Heart Health Hunt
This article was originally published in The Tan Sheet
An attorney for Pharmavite questions federal regulators' apparent pursuit of cholesterol-lowering products after the firm satisfies a Federal Trade Commission investigation by revising marketing language for its CholestOff dietary supplement
You may also be interested in...
FDA's warning letter to General Mills concerning cardiovascular health claims linked to Cheerios reflects a newly empowered agency and foreshadows aggressive regulatory activity to come, experts say
Wyeth says both science and FDA support the claims for Centrum Cardio that the House Energy and Commerce Committee is questioning
FDA will allow the use of a phytosterol heart health claim on a broader range of foods, beverages and dietary supplements while it completes a final rule on the issue, according to a Feb. 14 open letter posted on the agency's Web site